Anebulo Pharmaceuticals, Inc. (ANEB)
NASDAQ: ANEB · Real-Time Price · USD
0.4347
-0.0383 (-8.10%)
At close: Feb 23, 2026, 4:00 PM EST
0.4237
-0.0110 (-2.53%)
After-hours: Feb 23, 2026, 7:07 PM EST

Anebulo Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Selling, General & Admin
5.364.924.766.183.871.34
Research & Development
3.744.33.555.62.962.27
Operating Expenses
9.19.228.3111.786.833.61
Operating Income
-9.1-9.22-8.31-11.78-6.83-3.61
Interest Expense
-0.3-0.38-0.15---0.01
Interest & Investment Income
0.420.260.250.090.010
Other Non Operating Income (Expenses)
10.860.01-0.04-0-26.63
Pretax Income
-7.98-8.48-8.2-11.73-6.83-30.25
Net Income
-7.98-8.48-8.2-11.73-6.83-30.25
Preferred Dividends & Other Adjustments
-----8.21
Net Income to Common
-7.98-8.48-8.2-11.73-6.83-38.46
Shares Outstanding (Basic)
413426252314
Shares Outstanding (Diluted)
413426252314
Shares Change (YoY)
55.97%30.97%2.98%7.41%71.49%13.44%
EPS (Basic)
-0.19-0.25-0.32-0.47-0.29-2.83
EPS (Diluted)
-0.19-0.25-0.32-0.47-0.29-2.83
EBIT
-9.1-9.22-8.31-11.78-6.83-3.61
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q